Spermosens AB (publ) ("Spermosens" or the "Company") today announces that it will host a live Q&A webcast on Thursday, 27 August 2026, at 12:00 CET. CEO Tore Duvold will address questions regarding the Company's recent announcements.
The session is organised as a dedicated Q&A to provide shareholders and other stakeholders with the opportunity to engage directly with the Company's CEO. The webcast follows the publication of the Company's Q2 2026 report and forms part of Spermosens' commitment to regular investor engagement, with Q&A sessions typically held approximately one week after the publication of each quarterly report.
Webcast Details
Spermosens Q&A | Join meeting in Teams | Microsoft Teams
Participation and Submission of Questions
The webcast is open to all interested parties. Participants are invited to submit questions in advance to ensure a focused and productive session. The Company may consolidate similar queries to address as many topics as possible during the live webcast.
About Spermosens AB
Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specialises in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market.
The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com.